PEAR Stock Overview
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines.
Pear Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.85|
|52 Week High||US$14.60|
|52 Week Low||US$1.34|
|1 Month Change||-32.73%|
|3 Month Change||5.71%|
|1 Year Change||-80.07%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-80.85%|
Recent News & Updates
|PEAR||US Healthcare Services||US Market|
Return vs Industry: PEAR underperformed the US Healthcare Services industry which returned -47.9% over the past year.
Return vs Market: PEAR underperformed the US Market which returned -18.9% over the past year.
|PEAR Average Weekly Movement||17.6%|
|Healthcare Services Industry Average Movement||10.3%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: PEAR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: PEAR's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular.
Pear Therapeutics, Inc. Fundamentals Summary
|PEAR fundamental statistics|
Is PEAR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PEAR income statement (TTM)|
|Cost of Revenue||US$8.09m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.22|
|Net Profit Margin||-265.26%|
How did PEAR perform over the long term?See historical performance and comparison